Physician profile
Jonathan Ellant
NPI 1306918669
$44,742.97
in general payments reported to CMS, 2019-2025
31 companies · $9,811 in 2025
The $9,811 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,671 · 2021: $6,338 · 2022: $1,045 · 2023: $1,506 · 2024: $8,024 · 2025: $9,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $6,330 · Education: $108 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,875.00 |
| Food and Beverage | $6,329.53 |
| Education | $107.83 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16,162.86 | 2019-2022 | |
| Glaukos Corporation | $10,840.01 | 2019-2025 | Idose, Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Rxsight INC | $2,948.20 | 2024-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $2,834.69 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Ivantis, INC | $2,700.84 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $2,424.45 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $1,118.64 | 2021-2025 | Clareon, Rocklatan, Unity |
| Sun Pharmaceutical Industries INC. | $633.31 | 2019-2025 | Cequa, Xelpros |
| Harrow Eye, LLC | $563.63 | 2023-2025 | Iheezo, Vevye, Triesence |
| Sight Sciences, INC. | $531.79 | 2020-2025 | Omni Surgical System |
| Abbvie INC. | $471.47 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $458.29 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $370.11 | 2019-2023 | |
| Lensar, INC. | $357.99 | 2025 | Lensar Laser System |
| Bausch & Lomb Americas INC. | $348.71 | 2022-2025 | Miebo, Vyzulta, Xiidra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $329.40 | 2022-2025 | Tyrvaya, Ryzumvi |
| New World Medical,INC. | $320.59 | 2023-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Aerie Pharmaceuticals, INC. | $221.16 | 2019-2021 | |
| Ocular Therapeutix, INC. | $199.34 | 2023-2025 | Dextenza |
| Carl Zeiss Meditec Cataract Technology INC. | $192.37 | 2023 | |
| Amgen INC. | $166.03 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $158.38 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.56 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $60.00 | 2022 | |
| Biotissue Holdings INC. | $46.46 | 2021-2022 | |
| Astellas Pharma US INC | $30.01 | 2024 | Izervay |
| Dompe US, INC. | $27.36 | 2024 | Oxervate |
| Alimera Sciences, INC. | $24.94 | 2024 | Yutiq, Iluvien |
| Shire North American Group INC | $24.08 | 2019 | |
| Thea Pharma INC. | $17.78 | 2024 | Iyuzeh |
| Akorn Operating Company LLC | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ellant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.